The double-blind, placebo-controlled study was carried out on 100 female patients with osteoarthritis between the ages of 40 and 70. Participants were randomly assigned 8g of Peptan or a placebo per day over six months. They were assessed at three stages: before treatment, at three months and then six months after treatment began.
The results confirmed that a daily intake of Peptan reduced knee joint pain in osteoarthritis patients and improved knee joint function. Plus, there were no changes in liver or kidney parameters.
Dr Janne Prawitt, general nutrition manager at Rousselot says: “Osteoarthritis is a leading source of limited mobility and joint pain for both men and women and its prevalence is set to increase as the population ages. Peptan is a natural active ingredient that can help firms meet the growing demand for functional products and supplements that aid healthy ageing and offer proven joint function benefits.”